Delivery Order 36F79724D0185-36C24526N0706
Award Date 7/1/26
Potential Completion Date 7/7/26
Potential Value $23K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on April 7, 2026, for Galafold 123 mg under the GSA Schedule Pharmaceuticals and Drugs (FSS-61-IB). The parent contract is a multiple-award Federal Supply Schedule vehicle (36F79724D0185) valued at $13.024 million, effective through August 31, 2029, enabling VA medical centers nationwide to procure specialized pharmaceutical products. Place of performance is Philadelphia, PA. The order is firm...
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on April 28, 2026, under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule for Galafold 123 mg. Performance is at Philadelphia, PA, with an ultimate completion date of May 4, 2026. The parent vehicle is the GSA Federal Supply Schedule contract (FSS-61-IB), a multiple-award schedule enabling VA networks nationwide to procure pharmaceutical products including enzyme replacement...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order valued at $21,891.21 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg on November 20, 2025, with an ultimate completion date of November 25, 2025. This firm fixed-price delivery order, with no set-aside designation, represents a task order placed under Amicus Therapeutics' existing Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The...
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg on August 6, 2025, with a ceiling value of $21,891.21. This firm fixed-price delivery order, which is expected to be completed by August 8, 2025, represents a task order under the parent Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The award was made without a set-aside designation and...
- This is a $21,891.21 firm fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is for the delivery of GALAFOLD 123 MG, an enzyme replacement therapy used to treat Fabry disease, to the VA's Veterans Integrated Service Network 5 (VISN 5) in Philadelphia, Pennsylvania. The contract was awarded on September 24, 2025 and has a completion date of September 29, 2025. The...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (Mid-Atlantic region), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg, an FDA-approved enzyme replacement therapy used to treat Fabry disease in veterans. This firm fixed-price delivery order, awarded on March 4, 2026, with an ultimate completion date of March 6, 2026, represents a child order under the parent Pharmaceuticals and Drugs Federal Supply...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (Mid-Atlantic region), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg, an FDA-approved enzyme replacement therapy for the treatment of Fabry disease. This firm fixed-price delivery order, awarded on February 8, 2026, with an ultimate completion date of February 10, 2026, represents a continuation of the vendor's extensive supply relationship with the VA. The...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order valued at $21,891.21 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease. This firm fixed-price delivery order, awarded on December 12, 2025, with a completion date of December 16, 2025, will be fulfilled at a facility in Philadelphia, PA. The contract does not utilize a set-aside designation and represents a task...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order to Amicus Therapeutics US, LLC on October 29, 2025, for the supply of Galafold 123 mg, a specialized pharmaceutical product used to treat Fabry disease. This firm fixed-price delivery order, valued at $21,891.21 with completion scheduled for October 31, 2025, will be delivered to a VA facility in Philadelphia, Pennsylvania. The award was made under the Pharmaceuticals and Drugs...
- This delivery order for $21,089.47 was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 to Amicus Therapeutics US, LLC on March 6, 2024. The order is placed against Amicus Therapeutics US, LLC's Pharmaceuticals and Drugs Federal Supply Schedule contract with the General Services Administration to provide 123mg capsules of Galafold (migalastat), a medication used to treat Fabry disease. No set-aside designation was applied to this...